AstraZeneca vaccine trial starts at Japan : Still stalled in US


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ AstraZeneca vaccine trial starts at Japan : Still stalled in US
AstraZeneca vaccine is crossing the hardles one at a time !

A vaccine trial for a front-runner Covid-19 shot from AstraZeneca Plc and the University of Oxford restarted in Japan after studies were halted globally last month when a U.K. participant became ill.

The phase I-II trials resumed after the Japanese regulator gave the go-ahead, according to a statement from AstraZeneca Friday. Studies in the U.K., Brazil, South Africa and India have also restarted in recent weeks.

The news follows the European regulator’s decision this week to begin an accelerated review of the potential shot, a move that could pave the way for the vaccine to become the first in the region to win approval. The “rolling review” allows regulators to see clinical data in real-time so that a vaccine or drug can be brought to the market more quickly if successful.

The British pharmaceutical company and university are still waiting for trials to resume in the U.S.Vaccine trials are currently halted in the US after a study participant in the United Kingdom was reported to have sustained a severe adverse event, thought at the time to be transverse myelitis. Trials have recommenced in the United Kingtom, as well as in South Africa, India and Brazil.

The day before EMA’s announcement of the commencement of the vaccine candidate’s rolling review, Reuters reported that the US Food and Drug Administration (FDA) was expanding an investigation into the AstraZeneca/Oxford candidate to look at earlier vaccine trials that investigated the ChAdOx1 vector for other disease indications.

Back at home, speaking at India Today Healthgiri Awards 2020, Guleria said it is really difficult to say when the vaccine will be available in the country. Also Read - Sputnik V: Trials For Russian Coronavirus Vaccine May Begin in India in Upcoming Weeks

He said from the ongoing trials to the effectiveness of the vaccine — developing a vaccine depends on a lot of factors. Also Read - DCGI Issues Notice to Serum Institute Over Suspension of COVID Vaccine Trial by AstraZeneca Abroad

Talking about the challenges of developing the vaccine, the AIIMS chief said that the big challenge after the vaccine is developed will be its production and distribution on such a large scale.

Responding to a question on Covid-19 peak, Guleria said cases have stabilised marginally over the past few days. He further added that if the current trend continues for the next two weeks, it could clear that India is past its peak.

The development comes at a time when India’s COVID-19 caseload inched closer to 64 lakh-mark with 81,484 infections reported in a day, while the number of people who recuperated from the disease crossed 53 lakh pushing the recovery rate to 83.70 per cent, the Union health ministry said on Friday.

Inputs from - www.Bloomberg.com 

Tags : #AstraZeneca #OxfordUniversityVaccine #JapanTrialStartedAstraZeneca #CovidVaccineNewsNov3 #EuropeanUnion #FDA

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026